Investors

Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.

Tevogen’s leadership team, with decades of drug development and global commercialization experience in several therapeutic areas, believes that affordable personalized immunotherapies are the next frontier of medicine, and that advanced science and disruptive business models are necessary to sustain and accelerate medical innovation.

The company has developed core organizational capabilities, successfully completed the proof-of-concept (POC) clinical trial of its lead product candidate, TVGN 489, in which no dose limiting toxicities or treatment-related adverse events were observed, established a robust research pipeline, and earned considerable brand recognition including Nobel Peace Prize nomination for its patient centric, purpose driven business model, all in less than two years since its formation.

Tevogen’s lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients who are unable to take or unlikely to benefit from currently available preventative or therapeutic options, as well as a subset of patients suffering from long COVID.

• No dose limiting toxicities or treatment-related adverse events, including Cytokine Release Syndrome
• Correction of lymphopenia, reduction of inflammatory markers and viral load
• Trial patients were infected by Delta and a wide range of Omicron variants

Our rapidly progressing clinical stage biotech is approaching its next point of inflection. Join us before our next growth spurt.

Corporate Executive Summary

Accessible Immunotherapies and Business Excellence Through Innovative Science

Corporate Overview

Purpose, Innovations, and Opportunity to Join Before Tevogen’s Next Growth Spurt

March 1st, 2023
Kindly fill out the form below to download the presentation.